SSY GROUP (02005) has announced that the group has obtained drug manufacturing registration approvals from China's National Medical Products Administration for Compound Sodium Acetate Electrolyte and Glucose Injection (250ml and 500ml) and Metoclopramide Hydrochloride Injection (2ml:10mg). Both products are classified as Category 3 chemical drugs and are considered to have passed consistency evaluations.
Compound Sodium Acetate Electrolyte and Glucose Injection is primarily used to supplement and maintain water and electrolytes, as well as provide energy, when oral administration is not possible or insufficient. Metoclopramide Hydrochloride Injection is an antiemetic medication mainly indicated for: (i) vomiting caused by chemotherapy, radiotherapy, surgery, head injuries, post-traumatic brain syndrome, sea and air operations, and drug reactions; (ii) symptomatic treatment of nausea and vomiting associated with various conditions such as acute gastroenteritis, biliary and pancreatic diseases, and uremia; (iii) use prior to diagnostic duodenal intubation to facilitate the procedure and during gastrointestinal barium X-ray examinations to reduce nausea and vomiting reactions and promote barium passage.
The group's metoclopramide hydrochloride active pharmaceutical ingredient has also been approved by the National Medical Products Administration for registration as an API used in marketed formulations.
Comments